Glaxo Group Limited

Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxo Wellcome Inc.

Glaxogrouplimited

Jonathan Henry Ellis

Volker Germaschewski

Paul Andrew Hamblin

Alan Peter Lewis

Susannah Karen Ford

Peter Ernest Soden

Stephanie Jane Clegg

Karen Louise Philpott

Umesh Kumar

Stephen Anthony Burbidge

Zdenka Ludmila Jonak

Trevor Anthony Kenneth Wattam

Nicholas Timothy Rapson

Paul Alexander Wilson

Christopher Plumpton

Eric Dobrzynski

Alexandre Eon-Duval

John Robert White

Ian Kirby

Ian M Tomlinson

Laurent S Jespers

Ruth McAdam

John Richard White

Claire Ashman

Ian Richard Catchpole

Rabinder Kumar Prinjha

Herve Jean-Clement Coste

George Kopsidas

Martin Orecchia

James Scott Crowe

Michael Steward

Michael Robert West

Rudolf Maria De Wildt

Robert Ian Grundy

Gerald Wayne Gough

Martin John Cassidy

Jean-Yves Marcel Paul Bonnefoy

Jean Shearin

Alexis Paul Godillot

Philippe Marc Louis Alard

Pamela Joan Thomas

Alexis Pual Godillot

Farhana Hussain

Michael Neil Burden

Martin Anibal Orecchia

Radha Shah

Tejash Shah

Ahmed Yasin

Ruth Mcadam

Thil Batuwangala

Michael J Molloy

Susannah K Ford

Alexandre c/o Glaxosmithkline Eon-Duval

Michael Robert Glaxosmithkline West

Nicholas Timothy c/o Glaxosmithkline Rapson

The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.

Method of treatment with humanized anti-IL-18 antibodies

The present invention discloses humanized anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.

Humanized anti-IL-18 antibodies

Antibodies that bind human &#x3b2;-amyloid peptide, methods of treating diseases or disorders characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.

Antibodies

Antigen binding proteins that bind &#x3b2;-amyloid peptide, in particular human &#x3b2;-amyloid peptide; methods of treating diseases or disorders characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, including age related macular degeneration and glaucoma type diseases and &#x3b2;-amyloid dependent cataract formation, with the antigen binding proteins; pharmaceutical compositions comprising the antigen binding proteins; and methods of manufacture.

Humanized anti-beta-amyloid antibodies

The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and &#x3b2;-amyloid dependent cataract formation, with antigen binding proteins that bind &#x3b2;-amyloid peptide and in particular human &#x3b2;-amyloid peptide.

Antigen binding proteins

The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.

Compounds

The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF.

IL-13 binding protein

The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.

Immunoglobulins

Antibodies that bind human &#x3b2;-amyloid peptide, methods of treating diseases or disorders characterised by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.

Antibodies against amyloid-&#x3b2; peptide

Humanised anti-interleukin-18 antibody

The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.

Humanised anti-MAG antibody or functional fragment thereof

The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases.

NOGO-a neutralising immunoglobulin for treatment of neurological diseases

The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Growing community of inventors

Stevenage, United Kingdom

Jonathan Henry Ellis